ACAD
ACADIACNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
DAYBUE is growing, NUPLAZID remains resilient, management reaffirmed FY2026 guidance, and the company has two dated 2H2026 program milestones supported by the May 2026 8-K exhibit.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +1.4.
What can break
Both remlifanserin and the Japan trofinetide program are binary catalysts; negative data would likely compress the multiple.
Momentum
27
Value
62
Sentiment
75
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $28.00 · Bull $34.00 · Bear $15.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $31.85
Why
Momentum27 · Δ7d +0.4
Value62 · Δ7d +0.0
Sentiment75 · Δ7d +1.4
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
27
34% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+5.1
Value
62
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.4
Sentiment
75
33% active weight
Current posture
7d trendImproving
Δ7d
+1.4
Δ21d
-3.6
Why this grade
Composite grade C. Momentum 26.7 / Value 62.0 / Sentiment 74.9
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$3.68B
Beta
0.66
Shares Out
169.18M
P/E (TTM)
16.8
P/S (TTM)
4.22
P/FCF (TTM)
44.70
Rev YoY
+11.3%
EPS YoY
+113.3%
Gross Margin
+91.9%
Op Margin
+23.0%
Net Debt
-$755.99M
Current Ratio
3.02
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology